Novartis AG | Cash Flow
Fiscal year is January-December. All values CHF Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
8,630
9,820
6,767
6,612
7,582
12,345
Depreciation, Depletion & Amortization
4,323
3,992
5,031
5,271
5,128
5,242
Other Funds
92
128
4
1
10
2,888
Funds from Operations
12,934
13,294
12,286
11,381
13,074
14,129
Changes in Working Capital
721
572
831
76
623
161
Net Operating Cash Flow
12,213
12,721
11,455
11,305
12,451
13,967
Capital Expenditures
3,132
3,116
3,375
2,836
2,703
Sale of Fixed Assets & Businesses
44
55
228
159
91
Purchase/Sale of Investments
74
3,185
415
91
166
Net Investing Cash Flow
3,108
806
10,384
3,390
3,098
Cash Dividends Paid - Total
5,655
6,234
6,396
6,379
6,393
Issuance/Reduction of Debt, Net
1,236
3,037
1,888
2,025
3,927
Net Financing Cash Flow
8,129
7,458
8,835
5,235
7,611
Net Change in Cash
1,052
5,800
8,039
2,298
1,824
Free Cash Flow
9,522
10,319
9,176
9,470
10,782
Deferred Taxes & Investment Tax Credit
-
-
-
-
748
570
Net Assets from Acquisitions
39
303
15,894
754
772
Other Sources
103
1,041
9,151
834
631
Change in Capital Stock
1,147
4,133
4,323
882
5,156
Exchange Rate Effect
76
270
275
381
83
Other Uses
159
55
79
884
179
About Novartis
View Profile
